» Articles » PMID: 30573039

The Current Approach to the Diagnosis of Myelodysplastic Syndromes

Overview
Journal Semin Hematol
Specialty Hematology
Date 2018 Dec 22
PMID 30573039
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic neoplasms that share key clinical and biologic features, including peripheral blood cytopenias, morphologic dysplasia, ineffective and clonal hematopoiesis, and a variable risk of transformation to acute myeloid leukemia. Diagnostic evaluation of MDS relies on morphologic assessment of the peripheral blood and bone marrow, conventional cytogenetics, and exclusion of secondary causes of dysplasia. The diagnosis of MDS has important clinical consequences, but it can be challenging and requires distinction from mimics. In this review, the principles of bone marrow interpretation with respect to the diagnosis and classification of MDS in the current era will be discussed, including accurate morphologic interpretation, use of flow cytometry and immunohistochemistry, appropriate use of cytogenetics, and the emerging role of molecular genetics.

Citing Articles

A potential predictive model based on machine learning and CPD parameters in elderly patients with aplastic anemia and myelodysplastic neoplasms.

Qi Y, Liu X, Ding Z, Yu Y, Zhuang Z BMC Med Inform Decis Mak. 2024; 24(1):379.

PMID: 39695587 PMC: 11654282. DOI: 10.1186/s12911-024-02781-z.


Genome sequencing in the management of myelodysplastic syndromes and related disorders.

Cazzola M, Malcovati L Haematologica. 2024; 110(2):312-329.

PMID: 39445412 PMC: 11788631. DOI: 10.3324/haematol.2023.284947.


Toll-Like Receptor 4, 2, and Interleukin 1 Receptor Associated Kinase4: Possible Diagnostic Biomarkers in Myelodysplastic Syndrome Patients.

Khalilian P, Eskandari N, Sharifi M, Soltani M, Nematollahi P Adv Biomed Res. 2024; 13:17.

PMID: 38525404 PMC: 10958736. DOI: 10.4103/abr.abr_67_23.


SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process.

Jiang M, Chen M, Liu Q, Jin Z, Yang X, Zhang W Front Oncol. 2023; 13:1116438.

PMID: 37007111 PMC: 10063959. DOI: 10.3389/fonc.2023.1116438.


Disruption of stem cell niche-confined R-spondin 3 expression leads to impaired hematopoiesis.

Kurtova A, Heinlein M, Haas S, Velten L, Dijkgraaf G, Storm E Blood Adv. 2022; 7(4):491-507.

PMID: 35914228 PMC: 9979769. DOI: 10.1182/bloodadvances.2022007714.